scholarly journals Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation

2017 ◽  
Vol 23 (4) ◽  
pp. 552-561 ◽  
Author(s):  
Shalini Shenoy ◽  
Emanuele Angelucci ◽  
Staci D. Arnold ◽  
K. Scott Baker ◽  
Monica Bhatia ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Late Effects ◽  
Research Priorities ◽  
Marrow Transplant ◽  
Future Research ◽  
Hematopoietic Stem

Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation–associated thrombotic microangiopathy

Blood ◽  
2011 ◽  
Vol 118 (6) ◽  
pp. 1452-1462 ◽  
Author(s):  
Benjamin L. Laskin ◽  
Jens Goebel ◽  
Stella M. Davies ◽  
Sonata Jodele
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Thrombotic Microangiopathy ◽  
Coagulation Cascade ◽  
Future Research ◽  
Hematopoietic Stem

Abstract Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenging diagnosis after hematopoietic stem cell transplantation. Although endothelial injury represents the final common pathway of disease, the exact pathophysiology of TA-TMA remains unclear. Potential causes include infections, chemotherapy, radiation, and calcineurin inhibitors. Recent literature addresses the roles of cytokines, graft-versus-host disease, the coagulation cascade, and complement in the pathogenesis of TA-TMA. Current diagnostic criteria are unsatisfactory, because patients who have received a transplant can have multiple other reasons for the laboratory abnormalities currently used to diagnose TA-TMA. Moreover, our lack of understanding of the exact mechanism of disease limits the development and evaluation of potential treatments. Short- and long-term renal complications contribute to TA-TMA's overall poor prognosis. In light of these challenges, future research must validate novel markers of disease to aid in early diagnosis, guide current and future treatments, prevent long-term morbidity, and improve outcomes. We focus on TA-TMA as a distinct complication of hematopoietic stem cell transplantation, emphasizing the central role of the kidney in this disease.

scholarly journals Establishment of the Brazilian Registry of Hematopoietic Stem Cell Transplantation, using the database the Center for International Blood and Marrow Transplant Research

JBMTCT ◽  
2021 ◽  
Vol 2 (2) ◽  
pp. p100
Author(s):  
Cinthya Corrêa Corrêa ◽  
Heliz Regina Alves Das Neves ◽  
Anderson João Simione ◽  
Bruna Letícia Da Silva Santos Geraldo ◽  
Marcelo Pasquini ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Marrow Transplant ◽  
National Database ◽  
Active Centers ◽  
Hematopoietic Stem ◽  
Blood And Marrow Transplant

The number of hematopoietic stem cell transplantation (HSCT) in Brazil is growing rapidly. To better understand the outcomes of HSCT in Brazil, strategies have been developed with the Center for International Blood and Marrow Transplant Research (CIBMTR), using its standardized registry structure and data sharing application. The methods adopted to establish the registry were through efforts to increase the Brazilian centers that report to CIBMTR included training courses for HSCT data managers, the officialization of a multicenter HSCT study using the CIBMTR structure and the partnership between Brazilian Society of Bone Marrow Transplantation (SBTMO) and the CIBMTR. Here we describe the history for establishing the HSCT Brazilian database using the CIBMTR back to center data and present the aggregated results since 2016. We found a significant increase in the numbers of active centers reporting to CIBMTR from 11 in 2016 to 21 in 2020 corresponding to higher numbers of transplants reported to the CIBMTR from 574 to 921 in that period. The model used to generate this national database was effective as it leverages existing infrastructure to assess the activity and outcomes of HSCT in Brazil.  

scholarly journals HEMATOPOIETIC STEM CELL TRANSPLANTATION IN EGYPT CHALLENGES AND SOLUTIONS

2020 ◽  
Vol 12 (1) ◽  
pp. e2020023
Author(s):  
Hossam Kamel Mahmoud ◽  
Gamaleldin Mohamed Fathy ◽  
Alaa Elhaddad ◽  
Omar Abdelrahman Fahmy ◽  
Mohamed Abdelmooti ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Marrow Transplant ◽  
Hematopoietic Stem ◽  
Hematological Disorders ◽  
Blood And Marrow Transplant ◽  
The Difference

Hematopoietic stem cell transplantation (HSCT) is now an established treatment modality with definitive indications for many hematological disorders. However, this line of treatment requires tremendous resources, and it becomes increasingly difficult for transplanters  practicing in the developing world to reconcile the difference between what is possible and what is available. On the basis of 30 years of experience and more than 4250 transplants , this article will focus on the challenges faced our HSCT program and how they were solved. The HSCT program in Egypt started in 1989 on a narrow scale and since that time we faced many challenges.In 1997, the transplant rate increased dramatically with the opening of  many HSCT units distributed allover Egypt. Our team is registered in the Center for International Blood and Marrow Transplant Research ,and the number of transplants performed till December 2019 exceeded 4000 cases (60% allogeneic and 40% autologous).

Sign in / Sign up

Export Citation Format

Share Document